The structure and function of the glucagon-like peptide-1 receptor and its ligands

被引:211
|
作者
Donnelly, Dan [1 ]
机构
[1] Univ Leeds, Fac Biol Sci, Leeds LS2 9JT, W Yorkshire, England
关键词
GLP-1; GPCR; exendin-4; exenatide; liraglutide; diabetes; glucagon; insulin; VASOACTIVE-INTESTINAL-PEPTIDE; GUINEA-PIG PANCREAS; N-TERMINAL DOMAIN; GLP-1; 7-36; AMIDE; IN-VITRO; INSULIN-SECRETION; DISPERSED ACINI; EXTRACELLULAR DOMAIN; PARATHYROID-HORMONE; BIOLOGICAL-ACTIVITY;
D O I
10.1111/j.1476-5381.2011.01687.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Glucagon-like peptide-1(7-36)amide (GLP-1) is a 30-residue peptide hormone released from intestinal L cells following nutrient consumption. It potentiates the glucose-induced secretion of insulin from pancreatic beta cells, increases insulin expression, inhibits beta-cell apoptosis, promotes beta-cell neogenesis, reduces glucagon secretion, delays gastric emptying, promotes satiety and increases peripheral glucose disposal. These multiple effects have generated a great deal of interest in the discovery of long-lasting agonists of the GLP-1 receptor (GLP-1R) in order to treat type 2 diabetes. This review article summarizes the literature regarding the discovery of GLP-1 and its physiological functions. The structure, function and sequenceactivity relationships of the hormone and its natural analogue exendin-4 (Ex4) are reviewed in detail. The current knowledge of the structure of GLP-1R, a Family B GPCR, is summarized and discussed, before its known interactions with the principle peptide ligands are described and summarized. Finally, progress in discovering non-peptide ligands of GLP-1R is reviewed. GLP-1 is clearly an important hormone linking nutrient consumption with blood sugar control, and therefore knowledge of its structure, function and mechanism of action is of great importance.
引用
收藏
页码:27 / 41
页数:15
相关论文
共 50 条
  • [31] Glucagon-like peptide-1 receptor agonists suppress water intake independent of effects on food intake
    McKay, Naomi J.
    Kanoski, Scott E.
    Hayes, Matthew R.
    Daniels, Derek
    AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 2011, 301 (06) : R1755 - R1764
  • [32] An intrinsic agonist mechanism for activation of glucagon-like peptide-1 receptor by its extracellular domain
    Yin, Yanting
    Zhou, X. Edward
    Hou, Li
    Zhao, Li-Hua
    Liu, Bo
    Wang, Gaihong
    Jiang, Yi
    Melcher, Karsten
    Xu, H. Eric
    CELL DISCOVERY, 2016, 2
  • [33] Glucagon-Like Peptide-1 Receptor Agonists and Brain Vascular Function
    Begic, Edin
    Causevic, Mirsada
    HEART LUNG AND CIRCULATION, 2021, 30 (11) : 1675 - 1680
  • [34] Eleven Amino Acid Glucagon-like Peptide-1 Receptor Agonists with Antidiabetic Activity
    Mapelli, Claudio
    Natarajan, Sesha I.
    Meyer, Jean-Philippe
    Bastos, Margarita M.
    Bernatowicz, Michael S.
    Lee, Ving G.
    Pluscec, Jelka
    Riexinger, Douglas J.
    Sieber-McMaster, Ellen S.
    Constantine, Keith L.
    Smith-Monroy, Constance A.
    Golla, Rajasree
    Ma, Zhengping
    Longhi, Daniel A.
    Shi, Dan
    Xin, Li
    Taylor, Joseph R.
    Koplowitz, Barry
    Chi, Cecilia L.
    Khanna, Ashish
    Robinson, Gordon W.
    Seethala, Ramakrishna
    Anatal-Zimanyi, Ildiko A.
    Stoffel, Robert H.
    Han, Songping
    Whaley, Jean M.
    Huang, Christine S.
    Krupinski, John
    Ewing, William R.
    JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (23) : 7788 - 7799
  • [35] Renoprotective mechanisms of glucagon-like peptide-1 receptor agonists
    Chen, J.
    Cooper, M. E.
    Coughlan, M. T.
    DIABETES & METABOLISM, 2025, 51 (03)
  • [36] Inhibitory effects of glucagon-like peptide-1 receptor on epilepsy
    Wen, Yuetao
    Wu, Kunlun
    Xie, Yanfeng
    Dan, Wei
    Zhan, Yan
    Shi, Quanhong
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2019, 511 (01) : 79 - 86
  • [37] Clinical pharmacology of glucagon-like peptide-1 receptor agonists
    Dimitrios Sfairopoulos
    Stavros Liatis
    Stelios Tigas
    Evangelos Liberopoulos
    Hormones, 2018, 17 : 333 - 350
  • [38] Glucagon-like peptide-1 structure, function and potential use for NIDDM
    Gefel, D
    Barg, Y
    Zimlichman, R
    ISRAEL JOURNAL OF MEDICAL SCIENCES, 1997, 33 (10): : 690 - 695
  • [39] The Discovery and Development of Glucagon-Like Peptide-1 Receptor Agonists
    Fang, Haowen
    Niu, Bing
    Chen, Qin
    CURRENT MEDICINAL CHEMISTRY, 2024, 31 (20) : 2921 - 2943
  • [40] Glucagon-like peptide-1, glucagon-like peptide-2, and lipid metabolism
    Lutz, Thomas A.
    Osto, Elena
    CURRENT OPINION IN LIPIDOLOGY, 2016, 27 (03) : 257 - 263